Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Veliparib in addition to carboplatin and paclitaxel for epithelial ovarian, fallopian tube, or primary peritoneal cancer	Carboplatin (Paraplatin) , Paclitaxel (Taxol; paclitaxel albumin) , Veliparib (ABT-888; NSC 737664)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download
Rucaparib maintenance therapy for ovarian, fallopian tube or primary peritoneal cancer after frontline platinum-based chemotherapy	Rucaparib (Rubraca; PF-1367338)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2022	View \| Download
Rucaparib (Rubraca) for platinum-sensitive, high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal or fallopian tube cancer	Rucaparib (Rubraca; PF-1367338)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download
Pembrolizumab addition to chemotherapy, followed by maintenance with olaparib for BRCA non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer – First-line	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2020	View \| Download
Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2017	View \| Download
Nivolumab for platinum-resistant advanced or recurrent ovarian cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Niraparib for advanced ovarian, fallopian tube or primary peritoneal cancer - maintenance therapy	Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Mirvetuximab Soravtansine for Platinum-resistant Ovarian Cancer	Mirvetuximab soravtansine (IMGN853)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download